0 (0%) | 03-28 20:26 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 40.4 | 1-year : | 47.18 |
Resists | First : | 34.59 | Second : | 40.4 |
Pivot price | 31.75 | |||
Supports | First : | 31.1 | Second : | 28.95 |
MAs | MA(5) : | 31.03 | MA(20) : | 31.39 |
MA(100) : | 27.34 | MA(250) : | 26.93 | |
MACD | MACD : | 0.3 | Signal : | 0.4 |
%K %D | K(14,3) : | 32 | D(3) : | 24.9 |
RSI | RSI(14): 57.4 | |||
52-week | High : | 35.59 | Low : | 15.43 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ RVMD ] has closed below upper band by 38.2%. Bollinger Bands are 10.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 32.54 - 32.69 | 32.69 - 32.83 |
Low: | 31.04 - 31.22 | 31.22 - 31.38 |
Close: | 31.93 - 32.23 | 32.23 - 32.5 |
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Thu, 28 Mar 2024
Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 1,500 Shares - MarketBeat
Wed, 27 Mar 2024
How Will the Market React to Revolution Medicines Inc (RVMD) Stock Getting a Bearish Rating - InvestorsObserver
Mon, 25 Mar 2024
(RVMD) On The My Stocks Page - Stock Traders Daily
Mon, 25 Mar 2024
Where Does Revolution Medicines Inc (RVMD) Stock Fall in the Biotechnology Field After It Has Fallen -0.97% This Week? - InvestorsObserver
Mon, 25 Mar 2024
Comparing Revolution Medicines (NASDAQ:RVMD) & Semper Paratus Acquisition (NASDAQ:LGST) - Defense World
Wed, 28 Feb 2024
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 165 (M) |
Held by Insiders | 1.6083e+008 (%) |
Held by Institutions | 2.4 (%) |
Shares Short | 16,950 (K) |
Shares Short P.Month | 0 (K) |
EPS | -4.5668e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -20 % |
Return on Assets (ttm) | 819.8 % |
Return on Equity (ttm) | -20.1 % |
Qtrly Rev. Growth | 1.158e+007 % |
Gross Profit (p.s.) | -62.23 |
Sales Per Share | -22.72 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -3.9 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -351 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -1.42 |
Price to Cash Flow | 4.44 |
Dividend | 0 |
Forward Dividend | 1.715e+007 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |